5.72M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Similar securities

Based on sector and market capitalization

Report issue